Spero Therapeutics, Inc.
SPRO
$2.38
-$0.05-2.06%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 14.19M | 5.87M | 15.04M | 13.47M | 10.20M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 14.19M | 5.87M | 15.04M | 13.47M | 10.20M |
| Cost of Revenue | 10.67M | 13.61M | 92.51M | 703.00K | 23.73M |
| Gross Profit | 3.52M | -7.73M | -62.42M | 12.77M | -13.53M |
| SG&A Expenses | 5.88M | 6.82M | 7.06M | 5.20M | 5.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.55M | 20.43M | 35.89M | 32.06M | 29.26M |
| Operating Income | -2.36M | -14.56M | -20.85M | -18.59M | -19.06M |
| Income Before Tax | -1.70M | -13.87M | -20.60M | -17.44M | -17.86M |
| Income Tax Expenses | -- | -- | 290.00K | -290.00K | -- |
| Earnings from Continuing Operations | -1.70M | -13.87M | -20.89M | -17.15M | -17.86M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.70M | -13.87M | -20.89M | -17.15M | -17.86M |
| EBIT | -2.36M | -14.56M | -20.85M | -18.59M | -19.06M |
| EBITDA | -2.36M | -14.56M | -20.85M | -18.59M | -19.06M |
| EPS Basic | -0.03 | -0.25 | -0.38 | -0.32 | -0.33 |
| Normalized Basic EPS | -0.02 | -0.15 | -0.23 | -0.20 | -0.21 |
| EPS Diluted | -0.03 | -0.25 | -0.38 | -0.32 | -0.33 |
| Normalized Diluted EPS | -0.02 | -0.15 | -0.23 | -0.20 | -0.21 |
| Average Basic Shares Outstanding | 56.03M | 55.38M | 54.54M | 54.12M | 53.96M |
| Average Diluted Shares Outstanding | 56.03M | 55.38M | 54.54M | 54.12M | 53.96M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |